You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

COVID-19 Bivalent mRNA Vaccines: Covering Variants in the Transition to Endemicity

  • Authors: Karine Lacombe, MD, PhD; Andrew Ustianowski, MBBS
  • CPD Released: 9/19/2022
  • Valid for credit through: 9/19/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.50 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US primary care physicians, infectious disease physicians, and public and preventative health specialists.

The goal of this activity is that learners will increase their knowledge of omicron and subvariant virology and immunology, the need for a bivalent mRNA COVID-19 vaccine, and data regarding these vaccines, including efficacy, immunogenicity, safety, and individual and public health benefits.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Data on current vaccine immune evasion of BA.5 subvariants
    • Data on current vaccine immune evasion of BA.4 / BA.5 subvariants
    • Efficacy of bivalent mRNA COVID-19 vaccines
    • Tolerability of bivalent mRNA COVID-19 vaccines


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Disclosures for additional planners can be found here.


Faculty

  • Karine Lacombe, MD, PhD

    Infectious Diseases Unit
    St Antoine Hospital
    Institut Pierre-Louis de Santé Publique
    Sorbonne Université
    Paris, France

    Disclosures

    Karine Lacombe, MD PhD, has the following relevant financial relationships:
    Consultant or advisor for: Diaccurate; Gilead; Janssen; Moderna; Merck Sharp & Dohme; SpikImm; ViiV Healthcare
    Research funding from: Merck Sharp & Dohme
    Owns bonds from: SpikImm

  • Andrew Ustianowski, MBBS

    Consultant Physician
    Regional Infectious Diseases Unit
    North Manchester General Hospital
    Manchester, United Kingdom

    Disclosures

    Andrew Ustianowski, MBBS, has the following relevant financial relationships:
    nsultant or advisor for: Gilead; GlaxoSmithKline; Merck; ViiV Healthcare
    Speaker or member of speakers bureau for: Gilead; GlaxoSmithKline; Merck; Sanofi; ViiV Healthcare
    Research funding from: Gilead; Merck; ViiV Healthcare; Vir Biotechnology

Editors

  • Shanthi Voorn, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Shanthi Voorn, PhD, has no relevant financial relationships.

  • Eloise Ballard, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Eloise Ballard, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Susan L. Smith, MN, PhD

    Associate Director, Accreditation and Compliance

    Disclosures

    Susan L. Smith, MN, PhD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

COVID-19 Bivalent mRNA Vaccines: Covering Variants in the Transition to Endemicity

Authors: Karine Lacombe, MD, PhD; Andrew Ustianowski, MBBSFaculty and Disclosures

CPD Released: 9/19/2022

Valid for credit through: 9/19/2023

processing....

Educational Impact Challenge

The goal of this activity is that learners will increase their knowledge of omicron and subvariant virology and immunology, the need for a bivalent mRNA COVID-19 vaccine, and data regarding these vaccines, including efficacy, immunogenicity, safety, and individual and public health benefits.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.